



University of Dundee

A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes

Chung, Karen K; Altmann, Daniel; Barkhof, Frederik; Miszkiel, Katherine; Brex, Peter A; O'Riordan, Jonathan

Published in:
Annals of Neurology

DOI:
[10.1002/ana.25637](https://doi.org/10.1002/ana.25637)

Publication date:
2019

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Chung, K. K., Altmann, D., Barkhof, F., Miszkiel, K., Brex, P. A., O'Riordan, J., ... Chard, D. T. (2019). A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. *Annals of Neurology*. <https://doi.org/10.1002/ana.25637>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Title: A thirty year clinical and MRI observational study of multiple sclerosis and clinically isolated syndromes

Running Head: Clinical outcomes 30-years following a CIS

Authors: Karen K Chung (MBBS)¹, Daniel Altmann (DPhil)^{1,2}, Frederik Barkhof (MD)^{1,3,4,5}, Katherine Miszkiel (BM hons)⁶, Peter A Brex (MD)⁷, Jonathan O’Riordan (MD)⁸, Michael Ebner (PhD)^{4,9,10}, Ferran Prados (PhD)^{1,4,11}, M Jorge Cardoso (PhD)¹⁰, Tom Vercauteren (PhD)¹⁰, Sebastien Ourselin (PhD)¹⁰, Alan Thompson (MD)^{1,5}, Olga Ciccarelli (PhD)^{1,5}, Declan T Chard (PhD)^{1,5}

Affiliations:

1. NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London
Institute of Neurology, UK
2. Medical Statistics Department, London School of Hygiene and Tropical Medicine,
London, UK
3. Department of Radiology and Nuclear Medicine, VU University Medical Centre,
Amsterdam, Netherlands

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ana.25637

4. Centre for Medical Image Computing (CMIC), Department of Medical Physics and Biomedical Engineering, University College London, UK
5. National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, UK
6. Lysholm Department of Neuroradiology, National Hospital of Neurology and Neurosurgery, UK
7. King's College Hospital NHS Foundation Trust, UK
8. Tayside MS Research Unit, Ninewells Hospital, Dundee, UK
9. Wellcome / EPSRC Centre for Interventional and Surgical Sciences, University College London, UK
10. School of Biomedical Engineering and Imaging Sciences, King's College London, UK
11. Universitat Oberta de Catalunya, Barcelona, Spain

Corresponding author: Karen Chung

Contact information for corresponding author:

Email: k.chung@ucl.ac.uk

Telephone: +44 (0)20 31087545

Address: NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College

London Institute of Neurology, 10-12 Russell Square, London WC1B 5EH, United Kingdom

Abstract

Objective Clinical outcomes in multiple sclerosis (MS) are highly variable. We aim to determine the long-term clinical outcomes in MS, and to identify *early* prognostic features of these outcomes.

Methods 132 people presenting with a clinically isolated syndrome (CIS) were prospectively recruited between 1984-87, and followed up clinically and radiologically 1, 5, 10, 14, 20 and now 30 years later. All available notes and magnetic resonance imaging (MRI) scans were reviewed, and MS was defined according to the 2010 McDonald criteria.

Results Clinical outcome data was obtained in 120 participants at 30 years. Eighty were known to have developed MS by 30 years. Expanded disability status scale (EDSS) scores were available in 107 participants, of whom 77 had MS: thirty-two (42%) remained fully ambulatory (EDSS \leq 3.5) all of whom had relapsing-remitting MS (RRMS), three (4%) had RRMS and EDSS $>$ 3.5, 26 (34%) had secondary progressive MS (all had EDSS $>$ 3.5), and MS contributed to death in 16 (20%). Of those with MS, 11 have been treated with a DMT. The strongest early predictors (within 5 years of presentation) of secondary progressive MS (SPMS) at 30 years were presence of baseline infratentorial lesions and deep white matter lesions at one year.

Interpretation Thirty years after onset, in a largely untreated cohort, there was a divergence of MS outcomes; some people accrued substantial disability early on, while others ran a more favourable long-term course. These outcomes could, in part, be predicted by radiological findings from within a year of first presentation.

Introduction

Multiple sclerosis (MS) is a highly variable condition: some people with MS accrue little or no neurological disability over decades^{1,2} while others have their life significantly shortened.³ With a view to preventing long-term disability there is growing interest in the early use of MS disease modifying therapies (DMTs) capable of inducing sustained remission, albeit with the caveat that these may themselves be associated with life-changing side effects.^{4,5} Given this, it is important that the approach to DMTs should, as far as possible, involve a personalized risk-benefit analysis, ideally early in the disease course.

About 85% of people with MS initially develop the relapsing-remitting (RR) form, and first present with a clinically isolated syndrome (CIS, an episode of neurological symptoms that at least partially resolves).⁶ Features associated with more favourable longer-term outcomes in MS include an early age at symptom onset, an initially RRMS course, optic neuritis (ON) or a predominantly sensory CIS, complete remission after a CIS, and a longer interval between the first and second relapse.^{1,7} Following a CIS, a higher initial brain lesion load and greater accrual of lesions over the first five years, measured on magnetic resonance imaging (MRI) scans, are associated with an increased likelihood of developing disability within 20 years.⁸ Lesions within the brainstem and spinal cord also appear to be associated with a greater risk of subsequent disability.^{9,10} Natural history studies have demonstrated that in the majority of people with

RRMS, it took over a decade for their mobility to become limited, and over two decades before they were immobile without aids.⁷ Given this, assessment of the relationships between early prognostic features and later outcomes ideally requires clinical follow-up of two decades or more.

In this study we considered two main questions: How diverse are clinical outcomes at 30 years following a CIS? Can we identify early on (within five years) those who will develop progressive MS or have their life shortened by MS? We addressed these questions using data from a unique cohort of people recruited prospectively following a CIS between 1984 and 1987.^{11,12} The group was followed up clinically and had MRI at 1, 5, 10, 14, 20 and now 30 years. As recruitment pre-dated the DMT era, the cohort was largely untreated.

Methods

Participants

One hundred and forty people with a CIS were prospectively recruited between 1984 and 1987 at the National Hospital of Neurology and Neurosurgery, and Moorfields Eye Hospital. Eight were subsequently found to have alternative diagnoses.⁷ The cohort has previously been followed up on five occasions since their baseline assessment. Participants underwent clinical

assessment and MRI brain scan at baseline, with subsequent follow-up at 1, 5, 10, 14, and 20 years.^{8, 11-15} This is an updated 30-year follow-up of the cohort. At one year, radiological without clinical data was obtained; at all other time-points both were acquired. The numbers of participants and their demographic characteristics at each time-point are detailed in Table 1.

CIS were classified as being an ON, transverse myelitis (TM) or brainstem syndrome, based on clinical features.

This study was approved by our institutional ethics committee and the National Research Ethics Service (15/LO/0650). All participants gave informed consent, written if they attended in person, or verbal if they provided clinical information by telephone only. For the deceased members of the cohort, death certificates were obtained where possible (27 death certificates obtained out of 29).

Clinical assessment

Expanded disability status scale (EDSS)¹⁶ scores were used to measure disability, retrospectively from notes and participant recall at baseline and at nadir, where clinical improvement had plateaued or at one year (whichever was earlier), and prospectively by examination or by telephone¹⁷ at later time-points. Baseline EDSS scores could not be determined in 14 participants due to the absence of notes and unclear recall. In participants not assessed at a

given time-point, EDSS scores were determined retrospectively from later records and scores from adjacent time-points. At 30 years, the paced auditory serial addition test (PASAT), an assessment of information processing speed, and brief international cognitive assessment for MS (BICAMS) scores were also obtained for those who attended for review.^{18,19} BICAMS have three components: the revised brief visuospatial memory test (BVMTR), the symbol digit modalities test (SDMT), and the California verbal learning test (CVLT).

MRI

At baseline, one and five years, scans were acquired using a Picker 0.5T system; at ten, 14 and 20 years, a 1.5T General Electric Signa; at 30 years, a 3T Philips Achieva. Proton density (PD) and/or T2-weighted scans were obtained at each time-point. Contiguous, axial slices were obtained, with slice thickness 5 or 10mm at baseline, 5mm at all other time-points, and 3mm at 30-years. At baseline, one and five years, in plane resolution was 1.2x1.2mm, TR 2000ms, TE 60ms; at ten, 14 and 20 years, in plane resolution 1.0x1.0mm, TR 2000ms, and TE 30/90ms, 14/98ms, and 17/102ms, respectively. At 30-years, in plane resolution 0.5x0.5mm, TR 4375 ms, TE 85ms. Figure 1 shows representative MRI scans from each time-point.

Clinical outcomes

Participants were classified as having either a CIS or MS based on the McDonald 2010 criteria.²⁰ Those with MS were further sub-classified as having this either on clinical (a further relapse or clinical progression) or radiological grounds (new lesions seen on MRI), and RRMS or secondary progressive (SP) MS.²¹ Death due to MS was determined by consensus review of death certificates or notes (where available) by KC and DC, where MS was either given as the cause of, or a clear contributing factor to, death. For example, aspiration pneumonia in someone with advanced MS, or a pulmonary embolus secondary to chronic immobility.

A working definition of 'non-disabling' MS at 30 years was an EDSS score of ≤ 3.5 (fully ambulatory, with or without abnormal neurological findings on examination).¹⁶ At 30-years disease course was classified as CIS, MS with $EDSS \leq 3.5$, MS with $EDSS > 3.5$, or death relating to MS. Recognising that the EDSS takes little account of cognition,²² we determined the proportion in each group who were found to have cognitive impairment on BICAMS. We also determined the proportion who remained in employment or who had retired at the national state pension age of 60 years.

MRI analysis

Film prints from baseline, one, five, and ten years were re-digitised using Vidar Diagnostic Pro Advantage film digitizer, and processed to reconstruct a digital image stack comparable with native stacks (Table 1).²³ For each participant, all available scans were reviewed side-by-side, using 3D Slicer version 4.4.²⁴ White matter (WM) lesions were marked by consensus (KC with FB, DC or both), with reference to preceding or subsequent scans, and then counted by KC. Whole brain, juxta-cortical (JC), periventricular (PV), infra-tentorial (IT) and deep white matter (DWM) lesions were counted separately. DMW lesions were defined as supra-tentorial lesions that were neither JC nor PV.

Statistics

Early prediction models were fitted from the perspective of earlier time-points, when future or final outcomes and diagnostic groups were unknown, and therefore, unless otherwise stated, include all available subjects, including those who remained classified as CIS. Univariable and multivariable logistic regression was used to identify early (baseline, one-year and five-year) predictors of the following three binary 30-year outcomes: i) 30-year EDSS \leq 3.5 versus 30-year EDSS $>$ 3.5 (including deaths due to MS, ie. EDSS=10 by 30 years; this EDSS cut-off was chosen a priori as more clinically meaningful and objective than the >3.0 vs ≤ 3.0 threshold; ii) SPMS

diagnosis by 30 years, including SPMS deaths, versus CIS and RRMS at 30 years; iii) death due to MS by 30 years versus all still alive at 30 years. Independent variables analysed are listed in the Results section. Additionally, for MS-associated death, a Cox proportional hazards model was used to identify the best predictors. All deceased participants, regardless of MS status and cause of death, contributed to the Cox survival analysis, censored at the time of death.

Individuals' whose deaths were unrelated to MS were not included in the models for 30-year outcomes. The categories for early EDSS, EDSS changes and lesion count predictors were categorised to generate approximately equal frequencies; binary lesion variables, where possible, were dichotomized a priori 1+ vs 0 lesions, or to equalize frequencies if 0/1+ resulted in a very unequal distribution. Resulting ordered categorial variables were naturally coded so that when entered into a model, the coefficient gave a linear test for monotonic trend across the increasing category levels, assuming equal steps between adjacent categories. When the ordinal lesion variables did not predict materially better than binary, models with binary lesion predictors were reported. For multivariable logistic and Cox models, manual backwards stepwise elimination of variables with $p > 0.05$ was used to identify the best subset of independent predictors. Age-adjusted comparisons of cognitive outcomes between groups at 30-years were performed using multiple regression of the cognitive measure on group indicators with age as covariate. Analyses were performed using Stata 15.1,²⁵ and statistical significance is reported at $p < 0.05$.

Results

Whole cohort

At 30-year follow-up, outcome data (including deaths) were obtained in 120 out of the original 132 participants. Twelve individuals declined or were not traceable. Twenty-nine individuals were deceased, of whom 19 had MS, and ten died with last known classification as CIS. Of these ten participants, three were last assessed at 20-years, one at 10-years, two at 5-years, two at 1-year, and two at baseline. The mean follow-up duration was 30.9 years. Table 1 summarises the number of participants with a known outcome at each time-point. In those alive at 30 years, the mean (SD) age was 61.6 (7.4) years, with 59 (65%) female and 32 (35%) male. In the 91 alive individuals, 30 remained classified as having had a CIS, and 61 had MS. In total 80 were known to have MS (61 alive and 19 deceased). BICAMS scores were obtained in 61 participants, 41 with MS and 20 with CIS. Table 2 shows baseline demographic and clinical features for all participants, based on 30-year outcome.

MS cohort

Of the 80 people known to have MS by 30 years, 19 were deceased. Sixteen died of complications relating to advanced MS (EDSS=10), two died of unrelated causes, and for one

the cause of death was unknown. All three were assessed and documented to have RRMS at 20-years, with EDSS scores of 2.5, 3.0 and 6.0. Of the 61 who were alive, 26 had SPMS and 35 RRMS. BICAMS scores were obtained in 41 (26 with $EDSS \leq 3.5$, 15 with $EDSS > 3.5$), and BICAMS z-scores (adjusted for age, sex and years of education) were available in 31 subjects who were ≤ 65 years of age. Subjects who did not complete the cognitive tests tended to be more physically disabled, both early (mean nadir EDSS 1.6 vs 0.8 for subjects who completed assessment) and later in the disease course (mean 30-year EDSS 6.0 vs 4.1). Eleven (14%) have had a DMT at some stage, all of which were first-line injectable drugs, with the earliest commencing ten years after MS diagnosis (when DMTs first became available in the UK). Of these, seven had SPMS at 30-years, and four had RRMS.

At 30 years, EDSS peaks were observed at 0, 2.0, 6.0 and 10, with the lowest points at 4.0 and 9.5 (Figure 2). All of the 26 with SPMS (34%) had $EDSS > 3.5$. Of the 35 (45%) with RRMS, 32 (42%) had $EDSS \leq 3.5$. Six people fulfilled 2010 MS diagnostic criteria on radiological rather than clinical grounds, and they all had $EDSS \leq 3.5$.

With regard to cognition, of the 32 with $EDSS \leq 3.5$, 21 had validated BICAMS z-scores, of whom two had a z-score of < -1.5 in one or more modalities. None of the 32 had retired early for medical reasons, and all remained in employment (full-time or part-time), or retired at the national state pension age (Figure 3). Age-adjusted cognitive measures in the group with MS

and EDSS \leq 3.5 were not significantly different from the CIS group: for PASAT, the MS with EDSS \leq 3.5 group (adjusted mean 42.32) was 9% worse than the CIS group (adjusted mean 46.31, difference -4.00, $p=0.26$, 95% CI -11.0, 3.0); for BVMTR (adjusted mean 25.89) 0.2% better than CIS (adjusted mean 25.84, difference 0.05, $p=0.97$, 95% CI -0.03, 3.4); for CVLT (adjusted mean 51.70) 1% worse than CIS (adjusted mean 52.41, difference -0.71, $p=0.83$, 95% CI -7.3, 5.8); for SDMT (adjusted mean 50.40) 7% worse than CIS (adjusted mean 54.39, difference -4.0, $p=0.10$, 95% CI -8.7, 0.7). In the group with MS and EDSS $>$ 3.5, cognitive measures were more substantially and significantly worse than the CIS group (except for CVLT): for PASAT, 23% worse (adjusted mean 35.63, difference -10.68, $p=0.008$, 95% CI -18.4, -2.9); for BVMTR 21% worse, (adjusted mean 20.40, difference -5.44, $p=0.006$, 95% CI -9.3, -1.6); for CVLT 9% worse (adjusted mean 47.92, difference -4.49, $p=0.23$, 95% CI -11.9, 2.9); and for SDMT 24% worse (adjusted mean 41.49, difference -12.90, $p<0.001$, 95% CI -18.3, -7.5).

Early predictors of 30-year outcome

Demographic and clinical features as predictors

Univariable predictors of 30-year outcomes are presented in Supplementary Table 1. There was no association of gender and disease duration with any of the 30-year outcome groups.

People presenting with a brainstem CIS were at greater risk than those presenting with either

ON or TM, of MS-related death, hazard ratio (HR) 2.87, $p=0.04$. This was consistent with the higher proportion of brainstem subjects with baseline IT lesion present (41%), compared to TM (19%) and ON (11%; chi-squared test, $p=0.009$). The change in EDSS from nadir to five-years was also largest in the brainstem CIS group (mean=1). Older people at presentation were at greater risk of MS-related mortality, HR 1.07 per year ($p=0.04$).

EDSS as a predictor

Figure 4 shows the EDSS trajectories over time, based on 30-year outcome: separation between groups becomes apparent at five years, and is more pronounced subsequently. Baseline EDSS scores were not significantly associated with 30-year outcome.

For prediction of SPMS following a CIS, there was no significant association with either baseline or nadir EDSS, but 5-year $EDSS \geq 2.5$ was a significant predictor: 18/25 (72%) in this group had developed SPMS by 30-years, compared to 18/84 (21%) in the 5-year $EDSS < 2.5$ group, with odds ratio (OR) 9.43 ($p < 0.001$, 95% confidence interval (CI) 3.4, 26.1), PPV 72%, NPV 79%, sensitivity 50%, specificity 90% and accuracy 77% (95% CI 68%, 85%). EDSS change from nadir to 5-years was a slightly stronger predictor than either the absolute 5-year EDSS value, or the change from baseline to 5-years: 13/14 (93%) of people who progressed by ≥ 2 EDSS points between nadir and 5-years had transitioned to SPMS, compared to 23/95 (24%), OR 40.7

($p < 0.001$, 95% CI 5.0, 328.2), PPV 93%, NPV 76%, sensitivity 36%, specificity 99%, accuracy 78% (95% CI 69%, 85%).

For MS-related death, five-year EDSS was the strongest early predictor in a survival analysis (there were no MS-related deaths by five years). Five-year $EDSS \geq 2.5$ versus < 2.5 gave a HR of 23.6 ($p < 0.001$, 95% CI 5.3, 105.9); in those with five-year $EDSS \geq 2.5$, 12/29 (41%) were deceased by 30-years, compared to 2/88 (2%) in those with $EDSS < 2.5$, PPV 41%, NPV 98%, sensitivity 86%, specificity 84% and accuracy 84% (95% CI 76%, 90%).

For predicting 30-year $EDSS \leq 3.5$ vs $EDSS > 3.5$ outcome, EDSS scores at nadir and five-years were significant, more so than EDSS changes between these time-points, and the predictive value of EDSS at five-years was, unsurprisingly, greater than at earlier time-points.

A greater proportion of people with nadir $EDSS \geq 2.5$ progressed to 30-year $EDSS > 3.5$, 11/14 (79%) compared to 33/91 (36%) in those with nadir $EDSS < 2.5$, OR 6.44 ($p = 0.007$, 95% CI 1.7, 24.8), PPV 79%, NPV 64%, sensitivity 25%, specificity 95%, and accuracy 66% (95% CI 56%, 75%); for 5-year $EDSS \geq 2.5$ the corresponding proportions were 57/78 (73%) vs 4/27 (15%), OR 15.6 ($p < 0.001$, 95% CI 4.8, 50.5), PPV 85%, NPV 73%, sensitivity 52%, specificity 93% and accuracy 76% (95% CI 67%, 84%).

Lesion counts and locations as predictors

Total baseline lesion count was a significant predictor ($p < 0.001$) of 30-year EDSS > 3.5 , with OR 1.84 (trend test $p < 0.001$, 95% CI 1.3, 2.5) per adjacent high lesion number category (0, 1-3, 4-10, 11-20, 21+); or the reciprocal OR, 0.54 for 30-year EDSS ≤ 3.5 . The strongest early MRI predictors of 30-year EDSS > 3.5 were the presence of: 1) baseline IT lesions, with 19/22 (86%) progressing to EDSS > 3.5 by 30-years, vs 25/74 (34%) of those without baseline IT lesions, OR 12.4, ($p < 0.001$, 95% CI 3.4, 46.0), accuracy 71% (95% CI 61%, 80%); 2) one-year DWM lesions, with 35/58 (60%) reaching EDSS > 3.5 vs 3/24 (13%), OR 10.7 ($p < 0.001$, 95% CI 2.8, 39.8), accuracy 68% (95% CI 57%, 78%); and 3) one-year IT lesions, 20/24 (83%) vs 18/58 (31%), OR 11.1 ($p < 0.001$, 95% CI 3.3, 37.2), accuracy 73% (95% CI 62%, 82%). For predicting 30-EDSS ≤ 3.5 , these odds ratios apply to the absence of these lesions.

Given 91% of those with 30-year EDSS > 3.5 had SPMS, the strongest MRI predictors for SPMS were the same; the presence of: baseline IT lesion, with 19/22 (86%) becoming SPMS, vs 20/84 (24%) for those without these lesions, OR 20.3 ($p < 0.001$, 95% CI 5.4, 75.6), accuracy 78% (95% CI 69%, 86%), DWM lesion at one-year, 32/62 (52%) vs 2/30 (7%), OR 14.9 ($p < 0.001$, 95% CI 3.3, 68.1), accuracy 65% (95% CI 55%, 75%) and IT lesion at one-year, 20/24 (83%) vs 14/68 (21%), OR 19.3 ($p < 0.001$, 95% CI 5.7, 65.6), accuracy 65% (95% CI 55%, 75%).

For MS-related mortality, in a survival analysis presence of baseline IT lesions had HR 3.9 (p=0.007, 95% CI 1.5,10.3); the proportion of deaths in those with these lesions was 8/23 (35%) vs 8/78 (10%) in those without, PPV 35%, NPV 90%, sensitivity 50%, specificity 82%, accuracy 77% (95% CI 68%, 85%); presence of 1-year IT lesions had HR 5.25 (p=0.003, 95% CI 1.8, 15.7), with corresponding proportions 9/26 (35%) vs 5/61 (8%), PPV 35%, NPV 92%, sensitivity 64%, specificity 77%, accuracy 75% (95% CI 64%, 83%).

Combined predictive models

Variables entered into multivariable predictive models, to determine best predictors, include: age at onset, gender, CIS type, disease duration, early EDSS scores and interval EDSS changes between time-points, number of relapses within the first five years; and early total lesion count, changes in total lesion count, and location-specific lesion counts. Overall, MRI-detected brain lesions proved more effective predictors of 30-year outcomes than EDSS: in multivariable models including both lesion and EDSS variables, the latter no longer contributed significantly, with their coefficients substantially reduced.

Tables 3 and 4 show the results for early prediction of 30-year EDSS>3.5 and 30-year SPMS.

For each of the two outcomes, two models are shown: up to one-year and up to five-years. IT and DWM lesions were the best predictors, with the addition of nadir-to-five-years EDSS

change in the SPMS prediction model. The up to one-year models show that subjects with neither baseline IT nor one-year DWM lesions had a 13% probability of 30-year EDSS>3.5 (so 87% probability of 30-year EDSS≤3.5), while subjects with at least one lesion of both types had 94% probability (95% CI 83%, 100%) of 30-year EDSS>3.5, and 94% probability of SPMS by 30-years. The up to five-years models show that subjects with ≤5 DWM lesions at five-years and EDSS change of <2 from nadir to five-years, had 11% probability of SPMS by 30-years; conversely subjects with >5 DWM lesions and ≥2 EDSS change had 96% probability (95% CI 86%, 100%) of SPMS.

For MS-related death, the best independent early predictors up to one-year were having ≥1 IT lesions at one-year, HR 3.6 (95% CI 1.1, 11.2; p=0.031) and nadir EDSS, HR 1.5 per additional EDSS score unit (95% CI 1.2, 2.0; p=0.003)

Discussion

This cohort provides a unique perspective on the long-term clinical and MRI evolution of relapse-onset MS. As MRI first became available in the 1980's, and DMTs in the 1990's, it is highly unlikely that such long-term, essentially natural history, data can be obtained again. The results from this study suggest that 30 years following symptom onset, there are three distinct MS outcomes: an RRMS group with little accrued disability (EDSS≤3.5), an SPMS group who all

had impaired mobility ($EDSS \geq 4.0$) and a group who have had their lives shortened by MS (all of whom had SPMS). The results also suggest that, at 30 years, cognitive assessment scores in the $EDSS \leq 3.5$ group were not significantly different from the CIS group, whereas in the $EDSS > 3.5$ group, they were worse. Thirty-year outcomes could, in part, be predicted by early EDSS scores and more robustly by MRI-derived regional lesion counts.

After allowing for other factors, 30-year outcomes were not independently associated with age at onset, gender, baseline EDSS and CIS type. MRI lesion counts proved to be better predictors than EDSS scores, and lesion location was more important than lesion number. There was more missing data for changes in lesion count than for absolute lesion counts, and this may be a factor in why new early lesions were not as predictive. Interestingly, while PV and JC lesions are highly relevant in the diagnosis of MS,²⁰ it was early IT and DWM lesions that had the greatest long-term prognostic value. For example, in people with baseline IT and DWM lesion by one year, the chances of having SPMS were 94%, while those with one or more IT lesions by one-year were five times more likely to have died due to MS than the rest of the cohort.

Conversely, absence of both baseline IT and 1-year DMW lesions gave an 87% probability of $EDSS \leq 3.5$ at 30-years. IT lesions have previously been linked with less favourable outcomes in people with MS, after a mean follow-up of 7.7 years.⁹

Considering the potential application of these results, treatment decisions are often made prospectively and increasingly early in the disease course, prognostic factors identified within a year of symptoms onset may prove more useful than those identified within five years.

However, favourable prognostic features at one-year may also not impact significantly on choices; instead the emergence of markers suggestive of more disabling outcomes may carry more weight.

Since this cohort was first recruited diagnostic criteria for MS have changed, and most significantly an MS diagnosis can now be made in people after only a single episode of symptoms, but who fulfil MRI criteria for dissemination of lesions in space and time.²⁰ In the present study, six individuals had MS diagnosed on radiological grounds (all had EDSS \leq 3.5 at 30 years, compared with 37% if diagnosed on clinical grounds). Thus, they appear to represent a clinically silent end of the MS spectrum, who would previously have been overlooked. With the routine use of DMTs, the long-term evolution of MS may be changing: in a large cohort of RRMS patients, where 62% were treated with DMTs, only 11.3% transitioned to SPMS after a 17-year period.²⁶

There are several study limitations. Firstly, this study used well-established clinical outcome measures. This is less controversial for physically disabling outcomes such as SPMS or MS-related deaths, but what is considered a 'non-disabling' outcome may differ substantially

depending on whose perspective it is from, and patient-reported outcomes have not been assessed.^{27,28} For example we have not included detailed assessments of fatigue and visual impairment, which may significantly affect functional outcomes in people with MS. With this in mind, the 'non-disabling' MS group identified in this study may more pragmatically be considered to be people with MS who have consistently low levels of disability with no progression, and less to gain from DMTs, rather than those who have no ill effects from MS.

Secondly, at the inception of this cohort, MRI was a new technique, and image quality was not as good as is achievable now; given this, analyses of the earlier images will be less reliable than later ones. Post-gadolinium sequences were not obtained at any time-point, and only limited T1-weighted images were obtained at 14- and 20-years, and as such we have not been able to assess active lesion inflammation at the time of scanning, or assess the early relevance of T1 'black holes' for longer-term outcomes. Thirdly, symptoms attributable to spinal cord involvement were not systematically assessed early on in this cohort, and spinal cord imaging not routinely obtained. Additionally, we were not able to obtain outcome data for 12 of the 132 original participants, nor were we able to obtain MRI scans in nine of the 30 classified as CIS: it is possible that some of these individuals would fulfil MS diagnostic criteria, although this is unlikely to change the main findings of this study. Twelve participants did not contribute to early MRI information, of whom seven were lost to 30-year follow-up; however, the similarity in their baseline demographic features to the rest of the cohort suggests it is unlikely our main

results are materially affected. It should also be noted that the cohort originated from one neurosciences centre, and therefore there may be limitations in generalizability.

With regard to EDSS data, particularly early in the study, these were not captured consistently.

In order to minimize inaccuracies, data from adjacent time-points, and from clinical records, where available, were used. However, it is worth noting that EDSS scores ≤ 3.5 are derived from symptoms and examination findings, while scores from four upwards represent thresholds of mobility impairment. Although a >3.0 vs ≤ 3.0 threshold has been proposed in the literature on 'benign' MS, our use of an EDSS threshold of ≤ 3.5 vs >3.5 at 30-years is more objectively interpretable, should minimize the impact of any inter- or intra-rater variabilities, and be more reliable in the predictive models. Further, only one participant in our sample would have been reclassified if a >3.0 vs ≤ 3.0 dichotomy was used, with little impact on the main results. With regard to cognition, it is worth noting that of those who did not complete cognitive assessment, when compared to those who did, a significantly higher proportion were more neurologically disabled. Given this, it is likely that we have underestimated the true magnitude of cognitive deficits in those who are more physically disabled, and it is also possible that the small differences observed between the EDSS ≤ 3.5 and CIS groups have been underestimated due to incomplete data.

In our statistical analyses, as the main focus of our study is on early (within five years) predictors of late outcomes (30 years), we have confined ourselves to investigating only the associations between these time-points, and not associations at all other time points. Analyses of the intermediate time-points would be of interest, but would answer different questions and lie outside the scope of the present paper. A further caveat is that some subgroups were small, resulting in estimated odds ratios that, while statistically significant, should be interpreted with caution, particularly where the odds ratios' confidence intervals are very wide. Classification properties of our multivariable models might be improved with probability cut-offs different from 0.5; however, we believed this optimisation may not be reliably generalizable, and preferred not to screen for the best classification.

Lastly, it is worth noting that ON as a presenting CIS has been associated with a more favourable outcome when compared with other presentations.¹ Fifty-two percent of the participants in this study presented with ON, while in another large prospective cohort study, 37% presented with ON.²⁹ Although there was no evidence of association between ON and 30-year outcome in this study, there may still be some bias towards more favourable outcomes.

In conclusion, the results of this study suggest a divergence of natural outcomes in people with MS 30 years after symptom onset: those with SPMS, who have developed greater disability and have a significant risk of their life being shortened by MS; and those classified as

having RRMS, who remained fully ambulatory, with no significant cognitive impairment, and who remained employed or retired at the expected age. The results also indicate that for less favourable outcomes, the die may be cast early. This suggests that there are people with MS who have more to gain from earlier use of higher efficacy DMTs, although also counsels caution when considering the blanket use of DMTs in early MS or following a CIS. The predictive models developed by this study include features that can be obtained in clinical practice, and so hopefully may inform risk-benefit analyses when considering DMTs. A key goal of future research is to determine what pathologically differentiates progressive from persistently non-progressive MS, with a view to targeting treatments that would substantially increase the chances a person with MS follow a less-disabling clinical course.

Acknowledgements

We are indebted to Professor David Miller and the late Professor W Ian McDonald for the inception, early data collection, and follow-up of this cohort. We thank all who participated in this study and all involved in data collection over the years, in particular Dr Leonora Fisniku for her work at the 20-year follow-up. We thank Dr Marios Yiannakas for undertaking the MRI scanning at 30-years, and the MS Society for their sustained funding of this work.

This study was funded by the MS Society of Great Britain and Northern Ireland [20; 984]. ME is partially funded by the UCL EPSRC Centre for Doctoral Training in Medical Imaging [EP/L016478/1]. MJC and SO are partially funded by the Wellcome Flagship Programme (WT213038/Z/18/Z) and Wellcome EPSRC CME (WT203148/Z/16/Z). TV and SO are partially funded by the Innovative Engineering for Health award (Wellcome Trust [WT101957] and EPSRC [NS/A000027/1]). FP is supported by the Guarantors of Brain. FB, AT, OC and DC are supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre.

Authors' contributions

DTC contributed to study concept and design.

KKC, DA, FB, KM, PAB, JO, ME, FP, MJC, TV, SO and DTC contributed to data acquisition and analysis.

KKC, DA, FB, AJT, OC and DTC contributed to drafting of the manuscript and figures.

Potential Conflicts of interest

The authors report no potential conflicts of interest.

References

- 1 Ramsaransing GSM, De Keyser J. Benign course in multiple sclerosis: A review. *Acta Neurol. Scand.* 2006; **113**:359–369.
- 2 Hawkins SA, McDonnell G V. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. *J Neurol Neurosurg Psychiatry* 1999; **67**:148–52.
- 3 Scalfari A, Knappertz V, Cutter G, *et al.* Mortality in patients with multiple sclerosis. *Neurology* 2013; **81**:184–92.
- 4 Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. *Acta Neurol Scand* 2017; **136**:168–86.
- 5 Auricchio F, Scavone C, Cimmaruta D, *et al.* Drugs approved for the treatment of multiple sclerosis: review of their safety profile. *Expert Opin Drug Saf* 2017; **16**:1359–71.
- 6 Miller DH, Chard FT, Ciccarelli O. Clinically isolated syndromes. *Lancet Neurology* 2012; **11**:157–69

- 7 Confavreux C, Vukusic C, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. *Brain* 2003; **126**:770-82.
- 8 Fisniku LK, Brex PA, Altmann DR, *et al.* Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. *Brain* 2008; **131**:808-17.
- 9 Tintore M, Rovira A, Arrambide G, *et al.* Brainstem lesions in clinically isolated syndromes. *Neurology* 2010; **75**:1933-8.
- 10 Brownlee WJ, Altmann DR, Alves Da Mota P, *et al.* Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. *Mult Scler* 2017; **23**:665-674.
- 11 Miller DH, Ormerod IE, McDonald WI, *et al.* The early risk of multiple sclerosis after optic neuritis. *J Neurol Neurosurg Psychiatry* 1988; **51**:1569-71.
- 12 Miller DH, Ormerod IEC, Rudge P, *et al.* The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord. *Ann Neurol* 1989; **26**:635-9.
- 13 Morrissey SP, Miller DH, Kendall BE, *et al.* The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of

multiple sclerosis. *Brain* 1993; **116**:135-46.

14 O’Riordan JI, Thompson AJ, Kingsley DPE, *et al.* The prognostic value of brain MRI in clinically isolated syndromes of the CNS. *Brain* 1998; **121**:495-503.

15 Brex PA, Ciccarelli O, O’Riordan JI, *et al.* A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. *N Engl J Med* 2002; **346**:158-64.

16 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983; **33**:1444-52.

17 Lechner-Scott L, Kappos L, Hofman M, *et al.* Can the Expanded Disability Status Scale be assessed by telephone? *Mult Scler* 2003; **9**:154-9.

18 Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. *Mult Scler* 1999; **5**:244-50.

19 Langdon DW, Amato MP, Boringa J, *et al.* Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). *Mult Scler J* 2012; **18**: 891-8.

- 20 Polman CH, Reingold SC, Banwell B, *et al.* Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. *Ann Neurol* 2011; **69**: 292–302.
- 21 Lublin, F, Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology* 1996; **46**: 907–11.
- 22 Amato MP, Zipoli V, Goretti B, *et al.* Benign multiple sclerosis: Cognitive, psychological and social aspects in a clinical cohort. *J Neurol* 2006; **253**: 1054–9.
- 23 Ebner M, Chung KK, Prados F, *et al.* Volumetric reconstruction from printed films: Enabling 30 year longitudinal analysis in MR neuroimaging. *Neuroimage* 2018; **165**: 238–50.
- 24 3D Slicer. <https://www.slicer.org/>
- 25 StataCorp. 2017. *Stata Statistical Software: Release 15*. College Station, TX: StataCorp LLC
- 26 Cree B, Gourraud PA, Oksenberg JR, *et al.* Long-term evolution of multiple sclerosis disability in the treatment era. *Ann Neurol* 2016; **80**:499–510.

- 27 Sayao A, Devonshire V, Tremlett H. Longitudinal follow-up of 'benign' multiple sclerosis at 20 years. *Neurology* 2007; **68**: 496–501.
- 28 Tallantyre EC, Major PC, Atherton MJ, *et al.* How common is truly benign MS in a UK population? *J Neurol Neurosurg Psychiatry* 2018; **0**:1–7
- 29 Tintore M, Rovira À, Río J, *et al.* Defining high, medium and low impact prognostic factors for developing multiple sclerosis. *Brain* 2015; **138**: 1863–74.

Figure Legends

Figure 1: Representative axial brain images from one participant, acquired at baseline (A), 5 years (B), 10 years (C), 14 years (D), 20 years (E) and 30 years (F). At baseline and 5 years only PD-weighted images were acquired, while at later time-points T2-weighted images were acquired and are shown. Please refer to the main text for a description of the scan acquisition parameters at each time-point.

Figure 2: EDSS scores at 30 years; EDSS scores were obtained from 107 individuals at 30 years. An EDSS score of 10 was only assigned to those where MS was known to have contributed to

death. In the three other people with MS who had died, the cause of death was either unrelated to MS or unknown, and no EDSS score was assigned.

Figure 3: Employment and retirement status in people with MS, by EDSS at 30 years (n=61)

Figure 4: EDSS trajectories over 30 years, by 30-year status

Table 1: Demographic characteristics, clinical classification, and data availability at each follow-up time-point

		Follow-up (years)						
		0	1	5	10	14	20	30
Participants assessed at each time-point (n)		132	108	94	80	68	104	91
Of those assessed	Mean age at presentation (years)	32*	32	31	32	32	32	30
	Female (n,%)	80 (61)	67 (62)	53 (56)	53 (66)	47 (69)	69 (66)	59 (65)
	Optic neuritis (n, %)	69 (52)	52 (48)	46 (49)	43 (54)	35 (51)	53 (51)	49 (54)
	Transverse myelitis (n, %)	36 (27)	31 (29)	27 (29)	25 (31)	23 (34)	29 (28)	27 (30)
	Brainstem syndrome (n, %)	27 (20)	25 (23)	21 (22)	12 (15)	10 (15)	22 (21)	15 (16)
Deaths (n)				3	5	7	10	29
Of those deceased	Death related to MS (n)				1	3	3	16
	MS, death not related (n)							2
	MS, undetermined cause (n)							1
	CIS, death unrelated to MS			3	4	4	7	10
Of those known to be alive	CIS (n)	132		44	27	17	30	30
	RRMS (MRI, n)	0		3	2	2	6	5
	RRMS (clinical, n)	0		44	40	37	43	30
	SPMS (n)	0		3	11	12	25	26
Total MRI brain scans (n)		132	108	91	66	55	77	63
MRI scan availability	Digital scans (n)	42	0	48	63	55	77	63
	Printed scans (n)	61	95	38	3	0	0	0
	Scans missing (n)	29+	13^	5±	0	0	0	0
Total EDSS assessment (n) excluding deaths related to MS		118#	NA	94	80	68	104	91
Telephone EDSS assessment (n)		0	0	0	0	11	27	25

*based on 127 patients; CIS onset date was not available in four individuals, all of whom were subsequently lost to follow-up; +historical lesion count data available in 16 participants;

^historical lesion count available in 9 participants; ±historical lesion count available in all 5 participants; #determined retrospectively; NA= not available

Table 2: Baseline demographic and clinical features for all participants, based on 30-year outcome


		Mean age at presentation (years)	Female (n, %)	CIS presentation (% of each 30-year outcome, % within each CIS presentation)		
				Optic neuritis	Brainstem	Transverse myelitis
Baseline total (n=132)		32	80 (61%)	69	27	36
30-year outcome	CIS (n=30)	31	20 (67%)	19 (63, 28)	3 (10, 11)	8 (27, 22)
	RRMS EDSS ≤3.5 (n=32)	30	20 (63%)	15 (47, 22)	7 (22, 26)	10 (31, 28)
	RRMS EDSS >3.5 (n=3)	26	2 (67%)	2 (66, 3)	0	1 (33, 3)
	SPMS (n=26)	32	17 (65%)	13 (50, 19)	5 (18, 19)	8 (31, 22)
	Deceased due to MS (n=16)	36	10 (63%)	7 (44, 10)	6 (38, 22)	3 (19, 8)
	Deceased with CIS (n=10)	35	4 (40%)	4 (40, 6)	3 (30,11)	3 (30, 8)
	Deceased with MS (not due to MS or unknown) (n=3)	40	2 (67%)	1 (33, 1)	2 (67, 7)	0
	Unknown outcome (n=12)	31	5 (42%)	8 (67, 12)	1 (8, 4)	3 (3, 8)

Table 3: Best independent early predictors of 30-year EDSS >3.5. All models include EDSS 10 at or before 30 years.

30-year EDSS >3.5, best independent predictors up to 1 year						
Predictor	Odds ratio	P-value	Predictor combinations			
	(95% CI)					
<i>Baseline infra-tentorial lesion count, ≥1 vs 0</i>	16.8 (2.0, 139.7)	0.009	0	0	≥1	≥1
<i>1-year deep white matter lesion count, >1 vs 0</i>	6.7 (1.7, 26.0)	0.006	0	≥1	0	≥1
Model predicted probabilities for 30-year EDSS >3.5 (95% CI)			13% (0, 26)	49% (33, 64)	– ^a	94% (83, 100)
Model predicted probabilities for 30-year EDSS ≤3.5 ^b			87%	51%	–	6%
Model n=80. Overall model accuracy using 0.5 probability cut-off (95% CI): 71% (60, 81).						
^a There were no subjects with this lesion combination.						
^b These probabilities and their CIs are 100% minus the >3.5 probabilities.						
30-year EDSS >3.5, best independent predictors up to 5 years						
Predictor	Odds ratio	P-value	Predictor combinations			
	(95% CI)					
<i>Baseline infra-tentorial lesion count, ≥1 vs 0</i>	8.0 (1.5, 41.4)	0.013	0	0	≥1	≥1
<i>5-year deep white matter lesion count, >5 vs ≤5</i>	5.1 (1.7, 15.6)	0.004	≤5	>5	≤5	>5
Model predicted probabilities for 30-year EDSS >3.5 (95% CI)			18% (5, 30)	52% (36, 71)	63% (22, 100)	90% (76, 100)
Model predicted probabilities for 30-year EDSS ≤3.5			82%	48%	37%	10%
Model n=79. Overall model accuracy using 0.5 probability cut-off (95% CI): 75% (64, 84).						

Table 4: Best independent early predictors of 30-year SPMS status. All models include EDSS 10 at or before 30 years.

30-year SPMS, best independent predictors up to 1 year						
Predictor	Odds ratio (95% CI)	P-value	Predictor combinations			
			<i>Baseline infra-tentorial lesion count, ≥1 vs 0</i>	26.0 (3.1, 215.0)	0.003	0
<i>1-yr deep white matter lesion count, ≥1 vs 0</i>	8.6 (1.8, 41.0)	0.007	0	≥1	0	≥1
Model predicted probabilities for 30-year SPMS (95% CI)			7% (0, 16)	38% (23, 53)	–	94% (83, 100)
Model n=89. Overall model accuracy using 0.5 probability cut-off (95% CI): 79% (69, 87)						
30-year SPMS, best independent predictors up to 5 years						
Predictor	Odds ratio (95% CI)	P-value	Predictor combinations			
			<i>5-yr deep white matter lesion count, >5 vs ≤5</i>	5.3 (1.7, 16.6)	0.005	≤5
<i>EDSS score change from nadir to 5-year, ≥2 vs <2</i>	31.1 (3.5, 279.9)	0.002	<2	≥2	<2	≥2
Model predicted probabilities for 30yr SPMS (95% CI)			11% (2, 21)	80% (46, 100)	41% (24, 57)	96% (86, 100)
Model n=85. Overall model accuracy using 0.5 probability cut-off (95% CI): 78% (67, 86)						



EDSS trajectories by 30-year outcome
Excluding deaths not related to MS

